Skip Navigation


IJE Advance Access originally published online on November 23, 2004
International Journal of Epidemiology 2005 34(1):21-27; doi:10.1093/ije/dyh327
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
34/1/21    most recent
dyh327v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Evans, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

IJE vol.34 no.1 © International Epidemiological Association 2004; all rights reserved.

Article

MORGAM (an international pooling of cardiovascular cohorts)

Alun Evans1,*, Veikko Salomaa2, Sangita Kulathinal2, Kjell Asplund3, François Cambien4, Marco Ferrario5, Markus Perola6, Leena Peltonen6, Denis Shields7, Hugh Tunstall-Pedoe8 and Kari Kuulasmaa2 for the MORGAM Project

1 Department of Epidemiology and Public Health, Mulhouse Building, Queen's University Belfast, Belfast BT12 6BJ, UK
2 KTL—National Public Health Institute, Department of Epidemiology and Health Promotion, Mannerheimintie 166, 00300 Helsinki, Finland
3 National Board of Health and Welfare, SE-10630 Stockholm, Sweden
4 INSERM U525, Faculté de Médecine Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75634 Paris Cedex 13, France
5 Università degli studi dell'Insubria, Medicina del Lavoro e Preventiva, Viale Borri 57, 21100 Varese, Italy
6 KTL—National Public Health Institute, Department of Molecular Medicine, Biomedicum, Haartmaninkatu 8, PO Box 104, 00251 Helsinki, Finland
7 Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland
8 Cardiovascular Epidemiology Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland

* Correspondence: Department of Epidemiology and Public Health, Mulhouse Building, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK. E-mail: a.evans@qub.ac.uk

Keywords GenomEUtwin, MORGAM, case–cohort study, cardiovascular risk, genetic epidemiology, prospective studies

Accepted 5 August 2004

The first 150 words of the full text of this article appear below.


    How did the study come about?
 
Dissatisfaction has been voiced over recent decades concerning the lack of a relevant cardiovascular disease (CVD) scoring system for European populations. Recently this deficiency has been repaired with the publication of SCORE,1 although nonfatal events are still not catered for. In addition, the entire sequence of the human genome has recently been published.2 Common chronic diseases, such as coronary heart disease (CHD) and stroke, may have a strong genetic component. They are, however, caused not by a single genetic defect but by the interactions of many genetic and environmental factors. Hence, they are often called complex, multifactorial diseases. Moreover, the biological effects of common genetic variants are likely to be small in magnitude; indeed, variants with large biological effects tend to be rare, for example familial hypercholesterolaemia. Investigators examining the genetic background of complex, multifactorial diseases should, therefore, realize that they are looking for interactions between genetic variants with small, . . . [Full Text of this Article]


    What does MORGAM cover, and how has this changed?
 
Statistical methods
Population stratification
Ethical issues
Further phenotypic study

    Who is included in the sample?
 

    How often have study participants been followed up?
 

    What has been measured?
 

    What is the attrition rate?
 
What has MORGAM found?
What are the main strengths and weaknesses?

    Can I get hold of the data? Where can I find out more?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BiostatisticsHome page
O. Saarela, S. Kulathinal, and J. Karvanen
Joint analysis of prevalence and incidence data using conditional likelihood
Biostat., July 1, 2009; 10(3): 575 - 587.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Asplund, J. Karvanen, S. Giampaoli, P. Jousilahti, M. Niemela, G. Broda, G. Cesana, J. Dallongeville, P. Ducimetriere, A. Evans, et al.
Relative Risks for Stroke by Age, Sex, and Population Based on Follow-Up of 18 European Populations in the MORGAM Project
Stroke, July 1, 2009; 40(7): 2319 - 2326.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
P Founti, F Topouzis, L van Koolwijk, C E Traverso, N Pfeiffer, and A C Viswanathan
Biobanks and the importance of detailed phenotyping: a case study--the European Glaucoma Society GlaucoGENE project
Br J Ophthalmol, May 1, 2009; 93(5): 577 - 581.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Cambien and L. Tiret
Genetics of Cardiovascular Diseases: From Single Mutations to the Whole Genome
Circulation, October 9, 2007; 116(15): 1714 - 1724.
[Full Text] [PDF]